The biochemistry of drug metabolism - An introduction part 3. Reactions of hydrolysis and their enzymes

Chemistry and Biodiversity

Volumn 4, Issue 9, 2007, Pages 2031-2122

  Testa, Bernard ^a   Krämer, Stefanie D ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLSALICYLIC ACID; ACICLOVIR; CAMPTOTHECIN; DIAMORPHINE; DILTIAZEM; FELBAMATE; FLUAZIFOP BUTYL; FLUOROURACIL; IRINOTECAN; KETOPROFEN; LANDIOLOL; METHYLPHENIDATE; METHYLPREDNISOLONE SODIUM SUCCINATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFAMSTAT; NALTREXONE; NAPROXEN; PETHIDINE; PRODRUG; PROPANIDID; PROPRANOLOL; REPIRINAST; SALICYLIC ACID; SALICYLURIC ACID; SUXAMETHONIUM; UNINDEXED DRUG; VALACICLOVIR; XENOBIOTIC AGENT;

BIOCHEMISTRY; CATALYSIS; CATALYST; CHEMICAL REACTION; CHEMICAL STRUCTURE; CLASSIFICATION; DEHALOGENATION; DEHYDRATION; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; EDITORIAL; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; HYDRATION; LOW DRUG DOSE; NONHUMAN; TRANSESTERIFICATION;

ACIDS; AMIDES; ANIMALS; EPOXY COMPOUNDS; ESTERASES; HUMANS; HYDROLASES; HYDROLYSIS; PEPTIDES; PHARMACEUTICAL PREPARATIONS;

EID: 34948885743     PISSN: 16121872     EISSN: 16121880     Source Type: Journal    
DOI: 10.1002/cbdv.200790169     Document Type: Editorial

References (300)

1. B. Testa, S. D. Krämer,'The Biochemistry of Drug Metabolism - An Introduction. Part 1. Principles and Overview', Chem. Biodiv. 2006, 3, 1053-1101.
2. B. Testa, S. D. Krämer, 'The Biochemistry of Drug Metabolism - An Introduction. Part 2: Redox Reactions and Their Enzymes', Chem. Biodiv. 2007, 4, 257-405.
3. B. Testa, J. M. Mayer, 'Hydrolysis in Drug and Prodrug Metabolism - Chemistry, Biochemistry, and Enzymology', Verlag Helvetica Chimica Acta, Zurich, and Wiley-VCH, Weinheim, 2003.
4. B. Testa, W. Soine, 'Principles of drug metabolism', in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, Vol. 2, p. 431-498.
5. B. Testa, 'Principles of drug metabolism 2: Hydrolysis and conjugation reactions', in 'ADME-Tox Approaches', Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. J. B. Taylor, D. J. Triggle, Elsevier, Oxford, 2007, p. 133-166.
6. B. Testa, 'Nonenzymatic contributions to xenobiotic metabolism', Drug Metab. Rev. 1982, 13, 25-50
7. B. Ketterer, 'Detoxication reactions of glutathione and glutathione transferases', Xenobiotica 1986, 16, 957-973
8. R. N. Armstrong, 'Structure, catalytic mechanism, and evolution of the glutathione transferases', Chem. Res. Toxicol. 1997, 10, 2-18.
9. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), 'Enzyme Nomenclature', www.chem.qmul.ac.uk/ iubmb/enzyme.
10. Brenda: The Comprehensive Enzyme Information System, www.brenda.uni-koeln.de
11. ExPASy Proteomics Server, www.expasy.org
12. Enzyme Structure Database, www.ebi.ac.uk/thornton-srv/databases/enzymes
13. The ESTHER Database, http://bioweb.ensam.inra.fr/ESTHER/definition.
14. R. A. Totah, A. E. Rettie, 'Principles of drug metabolism 3: Enzymes and tissues', in 'ADME-Tox Approaches', Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in'Comprehensive Medicinal Chemistry', 2nd edn., Eds. J. B. Taylor, D. J. Triggle, Elsevier, Oxford, 2007, p. 167-191.
15. N. W. McCracken, P. G. Blain, F. M. Williams, 'Human xenobiotic metabolizing esterases in liver and blood', Biochem. Pharmacol. 1993, 46, 1125-1129
16. W. N. Aldridge,'The esterases: perspectives and problems', Chem. Biol. Interact. 1993, 87, 5-13
17. T. Satoh, R Taylor, W. F. Bosron, S. P. Sanghani, M. Hosokawa, B. N. La Du, 'Current progress on esterases: from molecular structure to function', Drug Metab. Dispos. 2002, 30, 488-493.
18. F. J. Leinweber, 'Possible physiological roles of carboxylic ester hydrolases', Drug Metab. Rev. 1987, 18, 379-439.
19. T. Satoh, M. Hosokawa, 'The mammalian carboxylesterases: from molecules to functions', Annu. Rev. Pharmacol. Toxicol. 1998, 38, 257-288.
20. T. Imai, M. Imoto, H. Sakamoto, M. Hashimoto, 'Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption', Drug Metab. Dispos. 2005, 33, 1185-1190.
21. T. Imai, 'Human carboxylesterase isozymes: catalytic properties and rational drug design', Drug Metab. Pharmacokinet. 2006, 21, 173-185
22. M. Hosokawa, T. Furihata, Y. Yaginuma, N. Yamamoto, N. Koyano, A. Fujii, Y. Nagahara, T. Satoh, K. Chiba, 'Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes', Drug Metab. Rev. 2007, 39, 1-15.
23. M. I. Mackness, H. M. Thompson, A. R. Hardy, C. H. Walker, 'Distinction between 'A'-esterases and arylesterases. Implications for esterase classification', Biochem. J 1987, 245, 293-296
24. B. N. La Du, S. Adkins, C. L. Kuo, D. Lipsig, 'Studies on human serum paraoxonase/arylesterase', Chem. Biol. Interact. 1993, 87, 34
25. L. Briseno-Roa, J. Hill, S. Notman, D. Seller, A. P. Smith, C. M. Timperley, J. Wetherell, N. H. Williams, G. R. Williams, A. R. Fersht, A. D. Griffiths, 'Analogues with flourescent leaving groups for screening and selection of enzymes that efficiently hydrolyze organophosphorus nerve agents', J. Med. Chem. 2006, 49, 246-255.
26. S. L. Primo-Parmo, R. C. Sorenson, J. Teiber, B. N. La Du, 'The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family', Genomics 1996, 33, 498-507
27. D. K. Sanghera, C. E. Aston, N. Saha, M. I. Kamboh, 'DNA polymorphism in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease', Am. J Hum. Genet. 1998, 62, 20-24
28. Cascorbi, M. Laule, P. M. Mrozikiewicz, A. Mrozikiewicz, C. Andel, G. Baumann, I. Roots, K. Stangl, 'Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease', Pharmacogenetics 1999, 9, 755-761.
29. M. M. Benning, J. M. Kuo, F. M. Kaushel, H. M. Holden, 'Three-dimensional structure of phosphotriesterase: an enzyme capable of detoxifying organophosphate nerve agents', Biochemistry 1994, 33, 15001-15007
30. J. L. Vanhooke, M. M. Benning, F. M. Raushel, H. M. Holden, 'Three-dimensional structure of the zinc-containing phosphotriesterase with the bound substrate analog diethyl 4-methylbenzylphosphonate', Biochemistry 1996, 35, 6020-6025.
31. M. A. Sogorb, I. Sanchez, M. Lopez-Rivadulla, V. Cespedes, E. Vilanova, 'EDTA-resistant and sensitive phosphotriesterase activities associated with albumin and lipoproteins in rabbit serum', Drug Metab. Dispos. 1999, 27, 53-59.
32. R. J. Richter, C. E. Furlong, 'Determination of paraoxonase (PON1) status requires more than genotyping', Pharmacogenetics 1999, 9, 745-753
33. B. Mackness, M. I. Mackness, S. Arrol, W Turkie, R N. Durrington, 'Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon', Br J Pharmacol. 1997, 122, 265-168.
34. L. G. Costa, A. Vitalone, T. B. Cole, C. E. Furlong, 'Modulation of paraoxonase (PON1) activity', Biochem. Pharmacol. 2005, 69, 541-550.
35. D. Josse, P. Masson, 'Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity', Ann. Pharm. Fr. 2001, 59, 108-118.
36. B. N. La Du, S. Billecke, C. Hsu, R. W Haley, C. A. Broomfield, 'Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals', Drug Metab. Dispos. 2001, 29, 566-569.
37. H. Lu, J. Zhu, Y Zang, Y. Ze, J. Qin, 'Cloning, high level expression of paraoxonase-3 in Sf9 cells and pharmacological characterization of its product', Biochem. Pharmacol. 2005, 70, 1019-1025.
38. D. M. Shih, L. Gu, Y. R. Xia, M. Navab, W F. Li, S. Hama, L. W Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, A. J. Lusis, 'Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis', Nature 1998, 394, 284-287.
39. A. R Hernández, M. C. Gonzalvo, F. Gil, E. Villanueva, A. Pla, 'Divergent effects of classical inducers on rat plasma and microsomal fraction paraoxonase and arylesterase', Environ. Toxicol. Pharmacol. 1997, 3, 83-86.
40. R. X. Xu, A. M. Hassell, D. Vanderwall, M. H. Lambert, W D. Holmes, M. A. Luther, W. J. Roque, M. V. Milbrun, Y. Zhao, H. Ke, R. T Nolte, 'Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity', Science 2000, 288, 1822-1825
41. Q. Huai, Y Sun, H. Wang, D. Macdonald, R. Aspiotis, H. Robinson, Z. Huang, H. Ke, 'Enantiomer discrimination illustrated by the high-resolution crystal structures of type 4 phosphodiesterase', J Med Chem. 2006, 49, 1867-1873.
42. 'Enzymes of the Cholinesterase Family', Eds. D. M. Quinn, A. S. Balasubramanian, B. P. Doctor, P.Taylor, Plenum Press, New York, 1995.
43. R Taylor, Z. Radic, 'The cholinesterases: from genes to proteins', Annu. Rev. Pharmacol.. Toxicol. 1994, 34, 281-320
44. P. Taylor, 'The cholinesterases', J Biol. Chem. 1991, 266, 4025-4028
45. A. Chatonnet, O. Lockridge, 'Comparison of butyrylcholinesterase and acetylcholinesterase', Biochem. J. 1989, 260, 625-634.
46. C. E Bartels, W. Xie, A. K. Miller-Lindholm, L. M. Schopfer, O. Lockridge, 'Determination of the DNA sequences of acetylcholinesterase and butyry1cholinesterase from cat and demonstration of the existence of both in cat plasma', Biochem. Pharmacol. 2000, 60, 479-487.
47. N. A. Hosea, H. A. Berman, P. Taylor, 'Specificity and orientation of trigonal carboxylesters and tetrahedral alkylphosphonyl esters in cholinesterases', Biochemistry 1995, 34, 11528-11536;
48. J. E. Haux, G. B. Quistad, J. E. Casida, 'Phosphobutyrylcholinesterase: phosphorylation of the esteratic site of butyrylcholinesterase by ethephon [(2-chloroethyl)phosphoric acid] dianion', Chem. Res. Toxicol. 2000, 13, 646-651
49. W Luo, Q. Yu, S. S. Kulkarni, D. A. Parrish, H. W Holloway, D. Tweedie, A. Shafferman, D. K. Lahiri, A. Brossi, N. H. Greig, 'Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine', J. Med. Chem. 2006, 49, 2174-2185
50. F. Ekström, Y.-P. Pang, M. Boman, E. Artursson, C. Akfur, S. Börjegren, 'Crystal structures of acetylcholinesterase in complex with HI-6, ortho-7 and obidoxime: structural basis for differences in the ability to reactivate tabun conjugates', Biochem. Pharmacol. 2006, 72, 597-607.
51. B. Li, M. Sedlacek, I. Manoharan, R. Boopathy, E. G. Duysen, P. Masson, O. Lockridge, 'Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma', Biochem. Pharmacol. 2005, 70, 1673-1684.
52. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase', J Am. Chem. Soc. 1996, 118, 2340-2346.
53. S. R. Feaster, D. M. Quinn, B. L. Barnett, 'Molecular modeling of the structures of human and rat pancreatic cholesterol esterases', Protein Sci. 1997, 6, 73-79.
54. C. J. Masters, 'On the role of the peroxisome in the metabolism of drugs and xenobiotics', Biochem. Pharmacol. 1998, 56, 667-673
55. M. C. Hunt, J. Yamada, L. J. Maltais, M. W. Wright, E. J. Podesta, S. E. H. Alexson, 'A revised nomenclature for mammalian acyl-CoA thioesterases/ hydrolases', J Lipid Res. 2005, 46, 2029-2032.
56. T. Peters Jr., 'All about Albumin. Biochemistry, Genetics, and Medical Applications', Academic Press, San Diego, 1996
57. A. Salvi, P. A. Carrupt, J. M. Mayer, B. Testa, 'Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid', Drug Metab. Dispos. 1997, 25, 395-398
58. Y. Sakurai, S. F. Ma, H. Watanabe, N. Yamaotsu, S. Hirono, Y. Kurono, U. Kragh-Hansen, M. Otagiri, 'Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates', Pharm. Res. 2004, 21, 285-292.
59. a) 'Handbook of Proteolytic Enzymes', 2nd edn., Eds. A. J. Barrett, N. D. Rawlings, J. F. Woessner, Elsevier, Oxford, 2004
60. b) N. D. Rawlings, F. R. Morton, A. J. Barrett, 'MEROPS: the peptidase database', Nucleic Acids Res. 2006, 34, D270-D272
61. c) MEROPS, the Peptidase Database; http://merops.sanger.ac.uk/.
62. C. V. Jongeneel, J. Bouvier, A. Bairoch, 'A unique signature identifies a family of zinc-dependent metallopeptidases', FEBS Lett. 1989, 242, 211-214.
63. G. Dodson, A. Wlodawer, 'Catalytic triads and their relatives', Trends Biochem. Sci. 1998, 23, 347-352.
64. M. R. Redinbo, P. M. Potter, 'Mammalian carboxylesterases: from drug targets to protein therapeutics', Drug Discov. Today 2005, 10, 313-325.
65. R. M. Wadkins, J. L. Hyatt, X. Mei, K. J. P. Yoon, M. Wierdl, C. C. Edwards, C. L. Morton, J. C. Obenauer, K. Damodaran, P. Beroza, M. K. Danks, P. M. Potter, 'Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylases', J Med. Chem. 2005, 48, 2906-2915.
66. S. Bencharit, C. L. Morton, E. L. Howard-Williams, M. K. Dans, P. M. Potter, M. R. Redinbo, 'Structural insights into CPT-11 activation by mammalian carboxylesterases', Nat. Struct. Biol. 2002, 9, 337-342.
67. D. W. Christianson, 'Structural biol.ogy of zinc', Adv. Protein Chem. 1991, 42, 281-355.
68. C. Oefner, A. D'Arcy, M. Hennig, F K. Winkler, G. E. Dale, 'Structure of human neutral endopeptidase complexed with phosphoramidon', Protein Data Bank ID: Idmt,1999
69. H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, 'The Protein Data Bank', Nucleic Acids Res. 2000, 28, 235-242.
70. N. R. Srinavas, J. W. Hubbard, G. McKay, E. M. Hawes, K. K. Midha, 'In vitro hydrolysis of threo-methylphenidate by blood esterases. Differential and enantioselective interspecies variability', Chirality 1991, 3, 99-103.
71. J. Zhang, J. C. Burnell, N. Dumaual, W. F. Bosron,'Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1', J. Pharmacol. Exp. Ther. 1999, 290, 314-318.
72. H. G. Schaefer, D. Beermann, R. Horstmann, M. Wargenau, B. A. Heibel, J. Kuhlmann, 'Effect of food on the pharmacokinetics of the active metabolite of the prodrug repirinast', J Pharm. Sci. 1993, 82, 107-109.
73. B. Testa, 'Principles of Organic Stereochemistry', Dekker, New York, 1979.
74. G. Sabbioni, J. B. Jones, 'Enzymes in organic synthesis. 39. Preparations of chiral cyclic acid-esters and bicyclic lactones via stereoselective pig liver esterase catalyzed hydrolyses of cyclic meso diesters', J. Org. Chem. 1987, 52, 4565-457O.
75. a) G. Alibrandi, N. Micali, S. Trusso, A. Villari, 'Hydrolysis of aspirin studie by spectrophotometric and fluorometric variable-temperature kinetics', J. Pharm. Sci. 1996, 85, 1105-1108
76. b) D. K. Patel, L. J. Notarianni, P. N. Bennett, 'Comparative metabolism of high doses of aspirin in man and rat' Xenobiotica 1990, 20, 847-854.
77. L. J. Fraile, J. J. Aramayona, M. A. Bregante, M. A. Garcia, A. R. Abadia, 'Deacetylation of diltiazem by several rabbit tissues', Pharm. Res. 1996, 13, 1875-188O.
78. Y Yoshigae, T. Imai, A. Horita, M. Otagiri, 'Species differences for stereoselective hydrolysis of propranolol prodrugs in plasma and liver', Chirality 1997, 9, 661-666
79. Y. Yoshigae, T. Imai, M. Taketani, M. Otagiri, 'Characterization of esterases invoved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma', Chirality 1999, 11, 10-13.
80. S. Y. Yeb, C. W, Gorodetzky, R. L. McQuinn, 'Urinary excretion of heroin and its metabolites in man', J Pharmacol. Exp. Ther. 1976, 196, 249-256
81. S. Y. Yeh, R. L. McQuinn, C. W. Gorodetzky, 'Identification of diacetylmorphine metabolites in humans', J. Pharm. Sci. 1977, 66, 201-204
82. D. A. Barrett, A. L. P, Dyssegaard, P. N. Shaw, 'The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma', J. Pharm. Pharmacol. 1992, 44, 606-608.
83. M. R. Brzezinski, B. J. Spink, R. A. Dean, C. E. Berkman, J. R. Cashman, W. F. Bosron, 'Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs', Drug Metab. Dispos. 1997, 25, 1089-1096.
84. J. J. Rady, E Aksu, J. M. Fujimoto, 'The heroin metabolite, 6-monoacetyhnorphine, activates delta opiod receptors to produce antinociception in Swiss-Webster mice', J. Pharmacol. Exp. Ther. 1994, 268, 1222-1231.
85. M. Graffner-Nordberg, K. Sjödin, A. Tunek, A. Hallberg, 'Synthesis and enzymatic hydrolysis of esters, constituting simple models of soft drugs', Chem. Pharm. Bull. 1998, 46, 591-601.
86. S. Yamaori, N. Fujiyama, M. Kushihara, T. Funahashi, T. Kimura, I. Yamamoto, T. Sone, M. Isobe, T. Ohshima, K. Matsumura, M. Oda, K. Watanabe, 'Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis', Drug Metab. Pharmacokinet. 2006, 21, 147-155
87. S. Yamaori, E. Ukena, N. Fujiyama, T. Funahashi, T Kimura, I. Yamamoto, T Ohshima, K. Matsumura, M. Oda, K. Watanabe, 'Nafamostat is hydrolyzed by human liver cytosolic long-chain acyl-CoA hydrolase', Xenobiotica 2007, 37, 260-27O.
88. H. Bundgaard, N. M. Nielsen, 'Glycolamide esters as novel biolabile prodrug type for non-steroidal anti-inflammatory carboxylic acid drugs', Int. J Pharmaceut. 1988, 43, 101-110
89. L. K. Wadhwa, P. D. Sharma, 'Glycolamide esters of 6-methoxy-2-naphthylacetic acid as potential prodrugs - physicochemical properties, chemical stability and enzymatic hydrolysis', Int. J. Pharmaceut. 1995, 118, 31-39.
90. R. E. S. Bullingham, A. J. Nicholls, B. R. Kamm, 'Clinical pharmacokinetics of mycophenolate mofetil', Clin. Pharmacokinet. 1998, 34, 429-455.
91. H. Han, R. L. A. de Vrueh, J. K. Rhie, K. M. Y. Covitz, R L. Smith, C. P. Lee, D. M. Oh, W. Sadée, G. L. Amidon, '5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter', Pharm. Res. 1998, 15, 1154-1159
92. T. C. Burnette, J. A. Harrington, J. E. Reardon, B. M. Merrill, P. de Miranda, 'Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir', J Biol. Chem. 1995, 270, 15827-15831
93. C. Yang, H. Gao, A. K. Mitra, 'Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir', J. Pharm. Sci. 2001, 90, 617-624.
94. M. J. Cho, L. C. Haynes, 'Serum-catalyzed hydrolysis of metronidazole amino acid esters', J Pharm. Sci. 1985, 74, 883-885
95. N. M. Mahfouz, M. A. Hassan, 'Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility', J Pharm. Pharmacol. 2001, 53, 841-848.
96. L. Song, R. Bevins, B. D. Anderson, 'Kinetics and mechanism of activation of a-amino acid ester prodrugs of camptothecins', J Med. Chem. 2006, 49, 4344-4355.
97. 1,-selective blocker, in a dose escalation regimen in healthy male volunteers', Drug Metab. Pharmacokinet. 2005, 20, 337-344.
98. J. Rautio, H. Taipale, J. Gynther, J. Vepsalainen, T. Nevalainen, T. Jarvinen, 'In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen', J. Pharm. Sci. 1998, 87, 1622-1628.
99. C. Larsen, P. Kurtzhals, M. Johansen, 'Kinetics of regeneration of metronidazole from hemiesters of maleic acid, succinic acid and glutaric acid in aqueous buffer, human plasma and pig liver homogenate', Int. J. Pharm. 1988, 41, 121-129.
100. T. Furihata, M. Hosokawa, A. Fujii, M. Derbel, T. Satoh, K. Chiba, 'Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma', Biochem. Pharmacol. 2005, 69, 1287-1297
101. M. A. Avery, J. R. Woolfrey, 'Anti-inflammatory steroids ',in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Ed. D. J. Abraham, John Wiley & Sons, Hoboken, 2003, Vol. 3, p. 747-853.
102. T L. Huang, A. Székács, T. Uematsu, E. Kuwano, A. Parkinson, B. D. Hammock, 'Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of α-naphthol, β-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases', Pharm. Res. 1993, 10, 639-648
103. R. P. Lee, A. Parkinson, R G. Forkert, 'Isozyme-selective metabolism of ethyl carbamate by cytochrome P450 (CYP2El) and carboxylesterase (hydrolase A) enzymes in murine liver microsomes', Drug Metab. Dispos. 1998, 26, 60-65.
104. I. M. Kapetanovic, C. D. Torchin, C. D. Thompson, T A. Miller, R J. McNeilly, M. L. Macdonald, H. J. Kupferberg, J. L. Perhach, R. D. Sofia, J. M. Strong, 'Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro', Drug Metab. Dispos. 1998, 26, 1089-1095
105. C. M. Dieckhaus, W. L. Santos, R. D. Sofia, T. L. Macdonald, 'The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation', Chem. Res. Toxicol. 2001, 14, 958-964.
106. M. Xie, D. Yang, M. Wu, B. Xue, B. Yan, 'Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity', Drug Metab. Dispos. 2003, 31, 21-27
107. Y. Ando, Y. Hasegawa, 'Clinical pharmacogentics of irinotecan (CPT-11)', Drug Metab. Rev. 2005, 37, 565-574.
108. A. Buur, H. Bundgaard, 'Prodrugs of 5-fluorouracil. VIII. Improved rectal and oral delivery of 5-fluorouracil via various prodrugs. Structure-rectal absorption relationships', Int. J. Pharm. 1987, 36, 41-49.
109. Z. Shahrokh, E. Lee, A. G. Olivero, R. A. Matamoros, K. D. Robarge, A. Lee, K. J. Weise, B. K. Blackburn, M. F. Powell, 'Stability of alkoxycarbonylamidine prodrugs', Pharm. Res. 1998, 15, 434-441.
110. H. K. Vaddi, M. O. Hamad, J. Chen, S. L. Banks, P. A. Cooks, A. L. Stinchcomb, 'Human skin permeation of branched-chain 3-O-alkyl ester and carbonate prodrugs of naltrexone', Pharm. Res. 2005, 22, 758-765.
111. D. K. Kim, N. Lee, Y. W, Kim, K. Chang, J. S. Kim, G. J. Im, W. S. Choi, 1. Jung, T. S. Kim, Y. Y. Hwang, D. S. Min, K. A. Um, Y. B. Cho, K. H. Kim, 'Synthesis and evaluaiton of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl) purines as potential prodrugs of penciclovir', J Med. Chem. 1998, 41, 3435-3441.
112. F. C. Falkner, T. M. Twomey, A. P. Borger, D. Garg, D. Weidler, N. Gerber, I. W. Browder, 'Disposition of ampiroxicam, a prodrug of piroxicam, in man', Xenobiotica 1990, 20, 645-652.
113. M. Lakeram, A. J. Paine, D. J. Lockley, D. J. Sanders, R. Pendlington, B. Forbes, 'Transesterification of p-hydroxybenzoate esters (parabens) by human intestinal (Caco-2) cells', Xenobiotica 2006, 36, 739-749.
114. J. S. Markowitz, C. L. Devane, D. W. Boulton, Z. Nahas, S. C. Risch, F Diamond, K. S. Patrick, 'Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol', Drug Metab. Dispos. 2000, 28, 620-624
115. Z. Sun, D. J. Murry, S. P. Sanghani, W. I. Davis, N. Y. Kedishvili, Q. Zou, T. D. Hurley, W. F. Boston, 'Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CESIAV, J Pharmacol. Exp. Ther. 2004, 310, 469-476
116. K. S. Patrick, R. L. Williard, A. L. VanWert, J. J. Dowd, J. E. Oatis Jr., L. D. Middaugh, 'Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol', J. Med. Chem. 2005, 48, 2876-2881.
117. 6]ethanol: preliminary in vitro findings using a rat liver preparation', J. Pharm. Sci. 1997, 86, 1494-1496.
118. S. P. Jindal, T. Lutz, 'Mass spectrometric studies of cocaine disposition in animals and humans using stable isotope-labeled analogues', J. Pharm. Sci. 1989, 78, 1009-1014.
119. S. J. Gatley, 'Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase', Biochem. Pharmacol. 1991, 41, 1249-1254
120. R. B. Melchert, C. Göldlin, U. Zweifel, A. A. Welder, U. A. Boelsterli, 'Differential toxicity of cocaine and its enantiomers, (+)-cocaine and (-)-ψ-cocaine, is associated with stereoselective hydrolysis by hepatic carboxylesterases in cultured rat hepatocytes', Chem.-Biol. Interact. 1992, 84, 243-258.
121. W. Xie, C. V. Altamirano, C. F. Bartels, R. J. Speirs, J. R. Cashman, O. Lockridge, 'An improved cocaine hydrolase: The A328Y mutant of human butyry1cholinesterase is 4-fold more efficient', Mol. Pharmacol. 1999, 55, 83-91
122. H. Sun, M. L. Shen, Y.-P. Pang, O. Lockridge, S. Brimijoin, 'Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase', J. Pharmacol. Exp. Ther. 2002, 302, 710-716.
123. M. R. Brzezinski, T. L. Abraham, C. L. Stone, R. A. Dean, W. F. Bosron, 'Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine', Biochem. Pharmacol. 1994, 48, 1747-1755
124. L. M. Kamendulis, M. R. Brzezinski, E. V. Pindel, W. F. Bosron, R. A. Dean, 'Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterase', J. Pharmacol. Exp. Ther. 1996, 279, 713-717.
125. S. C. Laizure, T. Mandrell, N. M. Gades, R. B. Parker, 'Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases', Drug Metab. Dispos. 2003, 31, 16-20
126. R. A. Dean, J. Zhang, M. R. Brzezinski, W. F. Bosron, 'Tissue distribution of cocaine methyl esterase and ethyl transferase activities: Correlation with carboxylesterase protein', J. Pharmacol. Exp. Ther. 1995, 275, 965-971
127. J. A. Bourland, D. K. Martin, M. Mayersohn, 'In vitro transesterification of cocaethylene (ethylcocaine) in the presence of ethanol', Drug Metab. Dispos. 1998, 26, 203-206.
128. S. M. Roberts, D. L. Phillips, I. R. Tebbett, 'Increased blood and brain cocaine concentrations with ethanol cotreatment in mice', Drug Metab. Dispos. 1995, 23, 664-666.
129. P. F. Dodds, 'Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid synthesis', Prog. Lipid Res. 1995, 34, 219-247.
130. M. A. Diczfalusy, I. Björkhem, C. Einarsson, S. E. H. Alexson, 'Formation of fatty acid ethyl esters in rat liver microsomes', Eur. J. Biochem. 1999, 259, 404-411
131. B. S. Kaphalia, R. R. Fritz, G. A. S. Ansari, 'Purification and characterization of rat liver microsomal fatty acid ethyl and 2-chloroethyl ester synthase and their relationship with carboxylesterase (pl 6.1)', Chem. Res. Toxicol. 1997, 10, 211-218
132. T. Tsujita, M. Sumiyoshi, H. Okuda, 'Fatty acid alcohol ester-synthetizing activity of lipoprotein lipase', J. Biochem. 1999, 126, 1074-1079.
133. M. Laposata, 'Fatty acid ethyl esters: ethanol metabolites which mediate ethanol-induced organ damage and serve as markers of ethanol intake', Prog. Lipid Res. 1998, 37, 307-316
134. E. A. Laposata, L. L. Lange,'Presence of nonoxidative ethanol metabolism in human organs commonly damaged by ethanol abuse', Science 1986, 231, 497-499.
135. T. Loftsson, T. Thorsteinsson, M. Másson, 'Hydrolysis kinetics and QSAR investigation of soft antimicrobial agents', J. Pharm. Pharmacol. 2005, 57, 721-727.
136. 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers', Eur. J. Clin. Pharmacol. 2003, 59, 621-630
137. M. Strolin Benedetti, R. Coupez, R. Whomsley, J. M. Nicolas, P. Collart, E. Baltes, 'Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog', Xenobiotica 2004, 34, 281-30O.
138. W. J. Weiss, S. M. Mikels, P. J. Petersen, N. V. Jacobus, P. Bitha, Y. I. Lin, R. T Testa, 'In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1β-methylcarbapenems', Antimicrob. Agents Chemother. 1999, 43, 460-464.
139. 14C-oxaceprol in Beagle dogs after intramuscular and oral administration', Arzneim.-Forsch. 1990, 40, 200-206.
140. A. Lippi, M. Criscuoli, S. Canali, A. Subissi, 'Reductive metabolism and its role in the disposition of the hydroxamic angiotensin-converting enzyme inhibitor idrapril calcium in rat', Xenobiotica 1996, 26, 551-558.
141. 14C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans', Drug Metab. Dispos. 2001, 29, 60-69
142. 2]omapatrilat after oral administration to rats, dogs, and humans', Drug Metab. Dispos. 2003, 31, 67-75.
143. M. A. Miller, L. Thibert, F. Desjardins, H. Siddiqi, A. Dascal, 'Testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay', J. Clin. Microbiol. 1995, 33, 2468-247O.
144. M. E. Morris, G. Levy, 'Determination of salicylamide and five metabolites in biol.ogical fluids by HPLC', J. Pharm. Sci. 1983, 72, 612-617.
145. G. Miyamoto, H. Sasabe, N. Tominaga, N. Uegaki, M. Tominaga, T. Shimizu, 'Metabolism of a new inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(l H)-quinolinone (OPC-8212), in the rat, mouse, dog, monkey, and human', Xenobiotica 1988, 18, 1143-1155.
146. S. Kudo, K. Umehara, M. Hosokawa, G. Miyamoto, K. Chiba, T. Satoh, 'Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation', J. Pharmacol. Exp. Ther. 2000, 294, 80-88.
147. A. W. Nicholls, J. C. Lindon, S. Caddick, R. D. Farrant, I. D. Wilson, J. K. Nicholson, 'NMR spectroscopic studies on the metabolism and futile deacetylation of phenacetin in the rat', Xenobiotica 1997, 27, 1175-1186
148. 3: measurement of futile metabolic deacetylation via HPLC/MS-SPE-NMR and HPLC-ToF MS', Xenobiotica 2006, 36, 615-629.
149. R. J. Parker, J. M. Collins, J. M. Strong, 'Identification of 2,6-xylidine as a major lidocaine metabolite in human liver slices', Drug Metab. Dispos. 1996, 24, 1167-1173
150. S. E. H. Axelson, M. Diczfalusy, M. Halldin, S. Swedmark, 'Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine', Drug Metab. Dispos. 2002, 30, 643-647.
151. T. F. Woolf, L. L. Radulovic,'Oxicams: metabolic disposition in man and animals', Drug Metab. Rev. 1989, 21, 255-276
152. J. Schmid, U. Busch, G. Trummlitz, A. Prox, S. Kaschke, H. Wachsmuth, 'Meloxicam: metabolic profile and biotransformation products in the rat', Xenobiotica 1995, 25, 1219-1236.
153. C. J. Parli, E. Evenson, B. D. Potts, E. Beedle, R. Lawson, D. W. Robertson, J. D. Leander, 'Metabolism of the prodrug DEGA (N-(2,6-dimethylphenyl)-4-[diethylamino)acetyl]amino]benzamide) to the potent anticonvulsant LY201116 in mice. Effect of bis-(p-nitrophenyl)phosphate', Drug Metab. Dispos. 1988, 16, 707-711
154. B. D. Potts, S. Gabriel, C. J. Parli, 'Metabolism, disposition, and pharmacokinetics of a potent anticonvulsant, 4-amino-N-(2,6-dimethylphenyl)benzamide (LY201116), in rats', Drug Metab. Dispos. 1989, 17, 656-661.
155. N. M. Hooper, R. J. Hesp, S. Ticku, 'Metabolism of aspartame by human and pig intestinal microvillar peptidases', Biochem. J. 1994, 298, 635-639.
156. A Naruki, S. Mizutani, K. Goto, A Tsujimoto, H. Nakazato, A. Itakura, M. Mizuno, O. Kurauchi, F. Kikkawa, Y. Tomoda,'Oxytocin is hydrolyzed by an enzyme in human placenta that is identical to the oxytocinase of pregnancy serum', Peptides 1996, 17, 257-261
157. B. F. Mitchell, S. Wong, 'Metabolism of oxytocin in human decidua, chorion, and placenta', J. Clin. Endocrinol. Metab. 1995, 80, 2729-2733.
158. E. A. Brownson, T. J. Abbruscato, T. J. Gillespie, V. J. Hruby, T. P. Davis, 'Effect of peptidases at the blood brain barrier on the permeability of enkephalin', J. Pharmacol. Exp. Ther. 1994, 270, 675-680
159. 7 and other opioid peptides', Naunyn-Schmiedebergs Arch. Pharmacol. 1998, 357, 276-282.
160. E. Krondahl, A. Orzechowski, G. Ekström, H. Lennernä ,'Rat jejunal permeability and metabolism of μ-selective tetrapeptides in gastrointestinal fluids from humans and rats', Pharm. Res. 1997, 14, 1780-1785
161. E. Krondahl, H. von Euler-Chelpin, A. Orzechowski, G. Ekström, H. Lennernäs, 'Investigation of the in-vitro metabolism of three opioid tetrapeptides by pancreatic and intestinal enzymes', J. Pharm. Pharmacol. 2000, 52, 785-795.
162. V J. Hruby, 'Peptide science: exploring the use of chemical principles and interdisciplinary collaboration for understanding life processes', J. Med. Chem. 2003, 46, 4215-4231.
163. 'Pseudo-peptides in Drug Discovery', Ed. P. E. Nielsen, Wiley-VCH, Weinheim, 2004.
164. M. Schwalm, H. Schupke, A. Gasparic, a Krone, G. Peter, R. Hempel, T. Kronbach, M. Locher, W. Jahn, J. Engel, 'Disposition and metabolism of cetrorelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs', Drug Metab. Dispos. 2000, 28, 10-2O.
165. C. Garcia-Aparicio, M. C. Bonache, I. De Meester, A. San-Félix, J. Balzarim, M. J. Camarata, S. Velazquez, 'Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach', J. Med. Chem. 2006, 49, 5339-5351.
166. a) B. A. Hamelin, J. Turgeon, 'Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors', Trends Pharmacol. Sci. 1998, 19, 26-37
167. b) E. S. Istvan, J. Deisenhofer, 'Structural mechanism for statin inhibition of HMG-CoA reductase', Science 2001 292, 1160-1164
168. c) A. Endo, 'The origin of the statins', Int. Congr. Ser. 2004, 1262, 3-8.
169. a) U. Christians, W. Jacobsen, L. C. Floren, 'Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?', Pharmcol. Ther. 1998, 80, 1-34
170. b) M. J. Garcia, R. E Remoso, A. Sanchez Navarrro, J. R. Prous, 'Clinical pharmacokinetics of statins', Methods Find. Exp. Clin. Pharmacol. 2003, 25, 457-481
171. c) H. Fujino, T. Saito, Y. Tsunenari, J. Kojima, T. Sakaeda, 'Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors', Xenobiotica 2004, 34, 961-971
172. d) G. Caron, G. Ermondi, B. Testa, 'Predicting the oxidative metabolism of statins. An application of the MetaSite algorithm', Pharm. Res. 2007, 24, 480-501.
173. M. J. Kaufman,'Rate and equilibrium constants for acid-catalyzed lactone hydrolysis of HMG-CoA reductase inhibitors', Int. J. Pharmaceut. 1990, 66, 97-106.
174. S. Billecke, D. Draganov, R. Councel, P. Stetson, C. Watson, C. Hsu, B. N. La Du, 'Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters', Drug Metab. Dispos. 2000, 28, 1335-1342.
175. J. F Teiber, D. I. Draganov, B. N. La Du, 'Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3', Biochem. Pharmacol. 2003, 66, 887-896.
176. D. E. Duggan, I. W. Chen, W. F Bayne, R. A. Halpin, C. A. Duncan, M. S. Schwartz, R. J. Stubbs, S. Vickers, 'The physiological disposition of lovastatin', Drug Metab. Dispos. 1989, 17, 166-173
177. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K. F. Sewing, U. Christians, 'Comparison of cytochrome P450-dependent metabolism and drug interactions of the HMG-CoA-reductase inhibitors lovastatin and pravastatin in the liver', Drug Metab. Dispos. 1998, 27, 173-179.
178. T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, J. H. Lin, P. G. Pearson, T. A. Baillie, 'Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization', Drug Metab. Dispos. 2002, 30, 505-512
179. H. Fujino, I. Yamada, S. Shimada, M. Yoneda, J. Kojima, 'Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization', Xenobiotica 2003, 33, 27-41.
180. T. Sakaeda, H. Fujino, C. Komoto, M. Kakumoto, J. Jin, K. Iwaki, K. Nishiguchi, T. Nakamura, N. Okamura, K. Okumura, 'Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport', Pharm. Res. 2006, 23, 506-512.
181. A. H. Kahns, J. Moss, H. Bundgaard, 'Improved oral bioavailability of salicylamide in rabbits by a 1,3-benzoxazine-2,4-dione prodrug', Int. J Pharm. 1992, 78, 199-202.
182. M. B. Maurin, S. M. Rowe, K. Blom, M. E. Pierce, 'Kinetics and mechnanism of hydrolysis of efavirenz', Pharm. Res. 2002, 19, 517-521.
183. M. M. Corsi, H. H. Maes, K. Wasserman, A. Fulgenzi, G. Gaja, M. E. Ferrero, 'Protection by L-2-oxothiazolidine-4-carboxylic acid of hydrogen peroxide-induced CDζ and CD3ζ chain downregulation in human peripheral blood lymphocytes and lymphokine-activated killer cells', Biochem. Pharmacol. 1998, 56, 657-662.
184. K. Abe, M. Yamada, T. Terao, H. Mizuno, Y. Matsuoka, R. Yorikane, T. Tokui, T. Ikeda, 'Novel organic nitrate prodrug (4R)-N-(2-nitroxyethyl)-2-oxothiazolidine-4-carboxamide (RS-7897) serves as a xenobiotic substrate for pyroglutamyl aminopeptidase I in dogs', Drug Metab. Pharmacokinet. 2003, 18, 373-38O.
185. S. Ikeda, F. Sakamoto, R. Hirayama, Y. Takebe, M. Sotomura, G. Tsukamoto, 'Studies on prodrugs. VIII. Preparation and characterization of (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl esters of sulbactam and its analogs', Chem. Pharm. Bull. 1988, 36, 218-226
186. K. Tougou, A. Nakamura, S. Watanabe, Y. Okuyama, A. Morino, 'Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent', Drug Metab. Dispos. 1998, 26, 355-359.
187. J. M. Ghuysen,'Serine beta-lactamases and penicillin-binding proteins', Annu. Rev. Microbiol. 1991, 45, 37-67
188. J. M. Frère, 'Beta-lactamases and bacterial resistance to antibiotics', Mol. Microbiol. 1995, 16, 385-395
189. A. L. Demain, R. P. Elander, 'The beta-lactam antibiotics: past, present, and future', Antonie van Leeuwenhoek 1999, 75, 5-19.
190. D. Andreotti, S. Biondi, E. Di Modugno, 'β-Lactam antibiotics', in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, Vol. 5, p. 607-735
191. C. Hubschwerlen, 'β-Lactam antibiotics', 'Therapeutic Areas II: Cancer, Infectious Diseases, Inflammation & Dermatology',Eds. J. J. Plattner, M. C. Desai, Vol. 7 in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. J. B. Taylor, D. J. Triggle, Elsevier, Oxford, 2007, p. 479-518.
192. M. Grover, M. Gulati, B. Singh, S. Singh, 'Correlation of penicillin structure with rate constant for basic hydrolysis', Pharm. Pharmacol. Commun. 2000, 6, 355-363
193. P. Imming, B. Klar, D. Dix, 'Hydrolytic stability versus ring size in lactams: implications for the development of lactam antibiotics and other serine protease inhibitors', J. Med. Chem. 2000, 43, 4328-4331
194. M. I. Page, A. P. Laws, 'The chemical reactivity of β-lactams, β-sultams and β-phospholactams', Tetrahedron Lett. 2000, 56, 5631-5638.
195. G. C. Bolton, G. D. Allen, B. E. Davies, C. W. Filer, D. J. Jeffery, 'The disposition of clavulanic acid in man', Xenobiotica 1986, 16, 853-863.
196. W. Krause, G. Kühne, 'Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey', Xenobiotica 1993, 23, 1277-1288.
197. R. Becker, E. Frankus, I. Graudums, W. A. Giinzler, E C. Helm, L. Flohé, 'The metabolic fate of supidimide in the rat', Arzneim.-Forsch. 1982, 32, 1101-1111.
198. J. Nakamura, T. Miwa, Y. Mori, H. Saski, 'Comparative studies on the anticonvulsant activity of lipophilic derivatives of γ-aminobutyric acid and 2-pyrrolidinone in mice', J Pharmacobiodyn. 1991, 14, 1-8.
199. A. Black, T. Chang, 'Metabolic disposition of rolziracetam in laboratory animals', Eur. J. Drug Metab. Pharmacokinet. 1987, 12, 135-143
200. A. H. Gouliaev, A. Senning, 'Piracetam and other structurally related nootropics', Brain Res. Rev. 1994, 19, 180-222.
201. B. B. Hasinoff, R. G. Aoyama, 'Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186), Chirality 1999, 11, 286-290
202. B. B. Hasinoff, R. G. Aoyama, 'Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat', Drug Metab. Dispos. 1999, 27, 265-268.
203. a) M. Reist, P. A. Carrupt, E. Francotte, B. Testa, 'Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites', Chem. Res. Toxicol. 1998, 11, 1521-1528
204. b) J. Lu, N. Helsby, B. D. Palmer, M. Tingle, B. C. Baguley, P. Kestell, L. M. Ching. 'Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans', J. Pharmacol. Exp. Ther. 2004, 310, 571-577.
205. R. Herzog, J. Leuschner, 'Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application', Arzneim.-Forsch. 1995, 45, 300-303.
206. N. E. Buss, A. G. Renwick, K. M. Donaldson, C. F. George, 'The metabolism of cyclamate to cyclohexylamine and its cardiovascular consequences in human volunteers', Toxicol. Appl. Pharmacol. 1992, 115, 199-209.
207. W. Sneader, 'Organic nitrates', Drug News Perspect. 1999, 12, 58-63
208. A. R. Butler, F. W. Flitney, D. L. H. Williams, 'NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective', Trends Pharmacol. Sci. 1995, 16, 18-22
209. H. Schröder, 'Bioactivation of organic nitrates and other nitrovasodilators', in 'Advances in Drug Research', Vol. 28, Eds. B. Testa, U. A. Meyer, Academic Press, London, 1996, p. 253-267.
210. T. Heimbach, D. M. Oh, L. Y. Li, N. Rodriguez-Hornedo, G. Garcia, D. Fleisher, 'Enzyme-mediated precipitation of parent drug from their phosphate prodrugs', Int. J. Pharm. 2003, 26, 81-92
211. T. Heimbach, D. M. Oh, L. Y. Li, M. Forsberg, J. Savolainen, J. Leppänen, Y. Matsunaga, G. Flynn, D. Fleisher, 'Absorption rate limit considerations for oral phosphate prodrugs', Pharm. Res. 2003, 20, 848-856.
212. A. Mäntylä, T. Garnier, J. Rautio, T. Nevalainen, J. Vepsälainen, A. Koskinen, S. L. Croft, T. Järvinen, 'Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone', J. Med. Chem. 2004, 47, 188-195.
213. J. Juntunen, J. Vepsäläinen, R. Niemi, K. Lame, T. Järvinen, 'Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether', J. Med. Chem. 2003, 46, 5083-5086
214. J. Juntunen, T. Järvinen, R. Niemi, 'In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs', J. Pharm. Pharmacol. 2005, 57, 1153-1157.
215. R. Niemi, J. Vepsäläinen, H. Taipale, T. Järvinen, 'Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid', J. Med. Chem. 1999, 42, 5053-5058.
216. C. R. Wagner, V. V. Iyer, E. J. Mclntee, 'Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides', Med. Res. Rev. 2000, 20, 417-451.
217. R. L. Mackman, T. Cihar, 'Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics', Annu. Rep. Med. Chem. 2004, 39, 305-321.
218. J. Van Gelder, S. Deferme, P. Annaert, L. Naesens, E. de Clercq, G. Van den Mooter, R. Kinget, P, Augustijns, 'Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism', Drug Metab. Dispos. 2000, 28, 1394-1396
219. R. Mallants, K. Van Oosterwyck, L. Van Vaeck, R. Mols, E. de Clereq, P. Augustijns, 'Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites', Xenobiotica 2005, 35, 1055-1066.
220. S. R. Khan, S. K. Kumar, D. Farquhar, 'Bis(carbamoyloxymethyl) esters of 2′,3′-dideoxyuridine 5′-monophosphate (ddUMP) as potential ddUMP prodrugs', Pharm. Res. 2005, 22, 390-396.
221. M. Shafiee, S. Deferme, A. L. Villard, D. Egron, G. Gosselin, J. L. Imbach, T. Lioux, A. Pompon, S. Varray, A. M. Aubertin, G. Van den Mooter, R. Kinget, C. Périgaud, P. Augustijns, 'New bis(SATE) prodrug of AZT 5′-monophosphate: in vitro anti-HIV activity, stability, and potential oral absorption', J. Pharm. Sci. 2001, 90, 448-463.
222. F. Worek, H. Thiermann, L. Szinicz, P. Eyer, 'Kinetic analysis of interactions between human acetyleholinesterase, structurally different organophosphorus compounds and oximes', Biochem. Pharmacol. 2004, 68, 2237-2248.
223. J. A. Vitarius, L. G. Sultatos, 'Kinetic mechanism of the detoxification of the organophosphate paraoxon by human serum A-esterase', Drug Metab. Dispos. 1994, 22, 472-478.
224. H. S. Lee, S. Jeong, K. Kim, J. H. Kim, S. K. Lee, B. H. Kang, J. K. Roh, 'In vitro metabolism of the new insecticide flupyrazofos by rat liver microsomes', Xenobiotica 1997, 27, 423-429.
225. G. B. Quistad, N. Zhang, S. E. Sparks, J. E. Casida, 'Phosphoacetylcholinesterase: Toxicity of phosphorus oxychloride to mammals and insects that can be attributed to selective phosphorylation of acetylcholinesterase by phosphorodichloridic acid', Chem. Res. Toxicol. 2000, 13, 652-657.
226. M. Jokanovic, M. Kosanovic, M. Maksimovic, 'Interaction of organophosphorus compounds with carboxylesterases in the rat', Arch. Toxicol. 1996, 70, 444-450.
227. W. F. Trager, 'Principles of drug metabolism 1: Redox reactions', in 'ADME-Tox Approaches', Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. J. B. Taylor, D. J. Triggle, Elsevier, Oxford, 2007, p. 87-132.
228. J. Meijer, J. W. DePierre, 'Cytosolic epoxide hydrolase', Chem.-Biol. Interact. 1988, 64, 207-249
229. J. K. Beetham, D. Grant, M. Arand, J. Garbarino, T. Kiyosue, F. Pinot, F. Oesch, W. R. Belknap, K. Shinozaki, B. D. Hammock, 'Gene evolution of epoxide hydrolases and recommended nomenclature', DNA Cell Biol. 1995, 14, 61-71
230. M. A. Argiriadi, C. Morisseau, B. D. Hammock, D. W. Christianson, 'Detoxification of environmental mutagens and carcinogens: Structure, mechanism, and evolution of liver epoxide hydrolase', Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10637-10642
231. L. W. Wormhoudt, J. N. Commandeur, N. P. Vermeulen, 'Genetic polymorphisms of human N-acetyl-transferase, cytochrome P450, glutathione S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity', Crit. Rev. Toxicol. 1999, 29, 59-124
232. A. J. Fretland, C. J. Orniecinski, 'Epoxide hydrolases: biochemistry and molecular biology', Chem.-Biol. Interact. 2000, 129, 41-59.
233. C. J. Omiecinski, L. Aicher, L. Swenson, 'Developmental expression of human microsomal epoxide hydrolase', J. Pharmacol. Exp. Ther. 1994, 269, 417-423
234. A. Gaedigk, J. S. Leeder, D. M. Grant, 'Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase', DNA Cell Biol. 1997, 16, 1257-1266
235. E. M. Laurenzana, C. Hassett, C. J. Omiecinski, 'Post-transcriptionaI regulation of human microsomal epoxide hydrolase', Pharmacogenetics 1998, 8, 157-167
236. A. L. Slit, N. J. Cherrington, C. D. Fisher, M. Negishi, C. D. Klaassen, 'Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto rats', Drug Metab. Dispos. 2006, 34, 1190-1197.
237. 1 oxide reductase of the vitamin K cycle', Biochem. Pharmacol. 1998, 55, 169-175
238. C. Morisseau, B. D. Hammock, 'Epoxide hydrolases: mechanism, inhibitor designs, and biological roles', Annu. Rev. Pharmacol. Toxicol. 2005, 43, 311-333
239. J. W. Newman, C. Morisseau, B. D. Hammock, 'Epoxide hydrolases: their roles and interactions with lipid metabolism', Prog. Lipid Res. 2005, 44,1-51.
240. J. Seidegard, G. Ekström, 'The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics', Environ. Health Perspect. 1997, 105, 791-799.
241. F. Pinot, D. F Grant, J. K. Beetham, A. G. Parker, B. Borhan, S. Landt, A. D. Jones, B. D. Hammock, 'Molecular and biochemical evidence for the involvement of the Asp333-His523 pair in the catalytic mechanism of soluble epoxide hydrolase', J. Biol. Chem. 1995, 270, 7968-7974
242. 523 form the catalytic triad of rat soluble epoxide hydrolase', J. Biol. Chem. 1996, 271, 4223-4229
243. R. N. Armstrong, C. S. Cassidy, 'New structural and chemical insight into the catalytic mechanism of epoxide hydrolases', Drug Metab. Rev. 2000, 32, 327-338
244. G. A. Gomez, C. Morisseau, B. D. Hammock, D. W. Christianson, 'Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis', Biochemistry 2004, 43, 4716-4723
245. A. Thomaeus, J. Carlsson, J. Åqvist, M. Widersten, 'Active site of epoxide hydrolases revisited: a noncannonical residue in potato StEH1 promotes both formation and breakdown of the alkylenzyme intermediate', Biochemistry 2007, 46, 2466-1479.
246. B. Borhan, A. D. Jones, F. Pinot, D. E Grant, M. J. Kurth, B. D. Hammock, 'Mechanism of soluble epoxide hydrolase. Formation of an a-hydroxy ester-enzyme intermediate through Asp-333', J. Biol. Chem. 1995, 270, 26923-26930
247. R. N. Armstrong, 'Kinetic and chemical mechanism of epoxide hydrolase', Drug Metab. Rev. 1999, 31, 71-86
248. E. Y. Lau, Z. E. Newby, T. C. Bruice, 'A theoretical examination of the acid-catalyzed and noncatalyzed ring-opening reaction of an oxirane by nucleophilic addition of acetate. Implications to epoxide hydrolases', J. Am. Chem. Soc. 2001, 123, 3350-3357
249. B. Schiøtt, T. C. Bruice, 'Reaction mechanism of soluble epoxide hydrolase: insights from molecular dynamics simulations', J. Am. Chem. Soc. 2002, 124, 14558-14570
250. K. H. Hopmann, F. Himo, 'Insights into the reaction mechanism of soluble epoxide hydrolase from theoretical active site mutants', J. Phys. Chem., B 2006, 110, 21299-21310.
251. R. A. Kemper, R. J. Krause, A. A. Elfarra, 'Metabolism of butadiene monoxide by freshly isolated hepatocytes from mice and rats: different partitioning between oxidative, hydrolytic, and conjugations pathways', Drug Metab. Dispos. 2001, 29, 830-836
252. J. L. Nieusma, D. J. Claffey, C. Maniglier-Poulet, T. Imiolczyk, D. Ross, J. A. Ruth, 'Stereoebemical aspects of 1,3-butadiene metabolism and toxicity in rat and mouse liver microsomes and feshly isolated rat hepatocytes', Chem. Res. Toxicol. 1997, 10, 450-456.
253. L. Cottrell, B. T. Golding, I Munter, W. P. Watson, 'In vitro metabolism of chloroprene: species differences, epoxide stereochemistry and a de-chlorination pathway', Chem. Res. Toxicol. 2001, 14, 1552-1562
254. T. Munter, L. Cottrell, T. Munter, W. P. Watson, 'Detoxication pathways involving glutathione and epoxide hydrolase in the in vitro metabolism of chloroprene', Chem. Res. Toxicol. 2003, 16, 1287-1297.
255. G. Bellucci, C. Chiappe, G. Ingrosso, 'Kinetics and stereochemistry of the microsomal epoxide hydrolase-catalyzed hydrolysis of cis-stilbene oxides', Chirality 1994, 6, 577-582.
256. G. Bellucci, G. Berti, C. Chiappe, A. Lippi, E Marioni, 'The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10,11-epoxide', J. Med. Chem. 1987 30, 768-773
257. I. Bernus, R. G. Dickinson, W. D. Hooper, M. J. Eadie, 'Dose-dependent metabolism of carbamazepine in humans', Epilepsy Res. 1996, 24, 163-172
258. R. E. Pearce, G. R. Vakkalagadda, J. S. Leeder, 'Pathways of carbamazepine bioactivation in vitro. I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites', Drug Metab. Dispos. 2002, 30, 1170-1179.
259. J. Marchant, 'Stop cancer before it starts', New Sci. 2001, 170(2285), 4.
260. W. W. Johnson, T. M. Harris, F. P. Guengerich, 'Kinetics and mechanism of hydrolysis of aflatoxin B1 exo-8,9-epoxide and rearrangement of the dihydrodiol', J. Am. Chem. Soc. 1996, 118, 8213-8220
261. W. W. Johnson, H. Yamazaki, T. Shimada, Y. F. Ueng, F. P. Guengerich, 'Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase', Chem. Res. Toxicol. 1997, 10, 672-676
262. F. P. Guengerich, W. W. Johnson, 'Kinetics of hydrolysis and reaction of aflatoxin B1 exo-8,9-epoxide and relevance to toxicity and detoxication', Drug Metab. Rev. 1999, 31, 141-158
263. F. P. Guengerich, H. Cai, M. McMahon, J. D. Hayes, T. R. Sutter, J. D. Groopman, Z. Deng, T. M. Harris, 'Reduction of aflatoxin B, dialdehyde by rat and human aldo-keto reductases', Chem. Res. Toxicol. 2001, 14, 727-737.
264. P. J. van Bladeren, J. M. Sayer, D. E. Ryan, P. E. Thomas, W. Levin, D. M. Jerina, 'Differential stereoselectivity of cytochrome P450b and P450c in the formation of naphthalene and anthracene 1,2-oxides. The role of epoxide hydrolase in determining the enantiomer composition of the 1,2-dihydrodiols formed', J Biol. Chem. 1985, 260, 10226-10235.
265. B. Oesch-Bartlomowicz, E Oesch, 'Mechanisms of toxification and detoxification that challenge drug candidates and drugs', in 'ADME-Tox Approaches', Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. I B. Taylor, D. I Triggle, Elsevier, Oxford, 2007, p. 193-214.
266. B. Testa, 'The Metabolism of Drugs and Other Xenobiotics - Biochemistry of Redox Reactions', Academic Press, London, 1995.
267. M. Shou, F. J. Gonzalez, H. V. Gelboin, 'Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 lA1, 1A2, and epoxide hydrolase', Biochemistry 1996, 35, 15807-15813.
268. R. T. Swank, E. K. Novak, L. Zhen, 'Genetic regulation of the subcellular localization and expression of glucuronidase', in 'Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity', Ed. F. C. Kauffman, Springer, Berlin, 1994, p. 131-160.
269. T. Akao, T. Akao, M. Hattori, M. Kanaoka, K. Yamamoto, T. Namba, K. Kobashi, 'Hydrolysis of glycyrrhizin to 18β-glycyrrhetyl monoglucuronide by lysosomal β-D-glueuronidase of animal livers', Biochem. Pharmacol. 1991, 41, 1025-1029
270. T. Akao, 'Distribution of enzymes involved in the metabolism of glycyrrhizin in various organs of rat', Biol. Pharm. Bull. 1998, 21, 1036-1044.
271. T. B. Vree, C. J. Timmer, 'Enterohepatic cycling and pharmacokinetics of oestradiol in postmeno-pausal women', J. Pharm. Pharmacol. 1998, 50, 857-864.
272. E. Palomino, E. H. Walker, S. L. Blumenthal, 'Carbohydrate prodrugs: Potential use for in situ activation and drug delivery', Drugs Future 1991, 16, 1029-1037
273. V. R. Sinha, R. Kumria,'Colonic drug delivery: prodrug approach', Pharm. Res. 2001, 18, 557-564.
274. H. W. Nolen III, D. R. Friend, 'Menthol-β-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome', Pharm. Res. 1994, 11, 1707-1711.
275. 6-benzylguanine-2′-deoxyguanosine', J. Med. Chem. 2005, 48, 256-261.
276. P. Riley, P. C. Figary, J. R. Entwisle, A. L. Roe, G. A. 'Mompson, R. Ohashi, N. Ohashi, T. J. Moorehead, 'The metabolic profile of azimilide in man: in vivo and in vitro evaluations', J. Pharm. Sci. 2005, 94, 2084-2095.
277. S. Rubnov, I. Shats, D. Levy, S. AmisaT, H. Schneider, 'Autocatalytic degradation and stability of obidoxime', J. Pharm. Pharmacol. 1999, 51, 9-14.
278. 3 receptor agonists', J. Med. Chem. 1995, 38, 4070-4079
279. 3-receptor agonist prodrug', J. PharmacoL Exp. Ther. 2000, 295, 219-225.
280. N. Bodor, A. Elkoussi, 'Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime - a new potential amiglaucoma agent', Pharm. Res. 1991 8, 1389-1395
281. L. Prokai, W. M. Wu, G. Somogyi, N. Bodor, 'Ocular delivery of the β-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analogue', J. Med. Chem. 1995, 38, 2018-2020.
282. M. Tramontini, L. Angiolini, 'Further advances in the chemistry of Mannich bases', Tetrahedron 1990, 46, 1791-1837
283. I. H. Pitman, 'Pro-drugs of amides, imides, and amines', Med. Res. Rev. 1981, 1, 189-214
284. J. J. Getz, R. J. Prankerd, K. B. Sloan, 'Mechanism of hydrolysis of benzamidomethyl derivatives of phenols and its implications for prodrug design', J. Org. Chem. 1992, 57, 1702-1706.
285. J. Alexander, M. L. Renyer, G. S. Rork, 'Investigation of N-[(acyloxy)alkyl] ester as a prodrug model for drugs containing the phenyltetrazole moiety', J. Pharm. Sci. 1994, 83, 893-897.
286. S. W. Larsen, M. Sidenius, M. Ankersen, C. Larsen, 'Kinetics of degradation of 4-imidazolinone prodrug types obtained from reacting prilocaine with formaldehyde and acetaldehyde', Eur J. Pharm. Sci. 2003, 20, 233-240.
287. L. Wlodek, H. Rommelspacher, R. Susilo, J. Radomski, G. Höfle, 'Thiazolidine derivatives as source of free L-cysteme in rat tissue', Biochem. Pharmacol. 1993, 46, 1917-1928
288. J. C. Roberts, H. L. Phaneuf, J. G. Szakacs, R. T. Zera, J. G. Lamb, M. R. Franklin, 'Differential chemoprotection against acetaminophen-induced hepatotoxicity by latentiated L-cysteines', Chem. Res. Toxicol. 1998, 11, 1274-1282
289. B. H. Wilmore, P. B. Cassidy, R. L. Warters, J. C. Roberts, 'Thiazolidine prodrugs as protective agents against γ-radiation-induced toxicity and mutagenesis in V79 cells', J. Med. Chem. 2001, 44, 2661-2666.
290. H. K. O. Osterheld, E. Musch, G. E. von Unruh, U. Loos, H. Rauscbecker, B. J. Mühlenbruch, 'A sensitive HPLC assay for metphalan and its hydrolysis products in blood and plasma', Cancer Chemother Pharmacol. 1988, 21, 156-162
291. M. G. Bolton, J. Hilton, K. D. Robertson, R. T. Streeper, O. M. Colvin, D. A. Noe, 'Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione', Drug Metab. Dispos. 1993, 21, 986-996.
292. G. F Bories, J. P. Cravedi, 'Metabolism of chloramphenicol: a story of nearly 50 years', Drug Metab. Rev. 1994, 26, 767-783.
293. 'Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug', Ed. B. Lippert, Verlag Helvetica Chimica Acta, Zurich, 1999.
294. D. F. Long, A. J. Repta, 'Cisplatin: Chemistry, distribution and biotransformation', Biopharm. Drug Dispos. 1981, 2, 1-16
295. N. Nagai, R. Okuda, M. Kinoshita, H. Ogata, 'Decomposition kinetics of cisplatin in human biological fluids', J. Pharm. Pharmacol. 1996, 48, 918-924
296. M. Jennerwein, P. A. Andrews, 'Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminodi-chloroplatinum(II)', Drug Metab. Dispos. 1995, 23, 178-184.
297. M. A. Allsopp, G. J. Sewell, C. G. Rowland, C. M. Rifley, R. L. Schowen, 'The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles', Int. J Pharm. 1991, 69, 197-210
298. S. B. Duffull, R A. Robinson, 'Clinical pharmacokinctics and dose optimisation of carboplatin', Clin. Pharmacokinet. 1997, 33, 161-183.
299. P. Allain, O. Heudi, A. Cailleux, A. Le Bouil, F. Larra, M. Boisdron-Celle, E. Gamelin, 'Early biotransformations of oxaliplatin after its intravenous administration to cancer patients', Drug Metab. Dispos. 2000, 28, 1379-1384
300. E. Jerremalm, M. Hedeland, I. Wallin, U. Bondesson, H. Ehrsson, 'Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex', Pharm. Res. 2004, 21, 891-894.